Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | CTSB | P07858 | 1/20 | 0.55 |
| ▸ | CTSS | P25774 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 1/20 | 0.55 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.54 |
| ▸ | TACR1 | P25103 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MME | P08473 | 1/20 | 0.53 |
| ▸ | ECE1 | P42892 | 1/20 | 0.53 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL330061 | 1.00 | CTSL (0.55) | CTSLCTSBCTSSCTSKITGB3 | |
| SCHEMBL8976911 | 1.00 | CTSL (0.55) | CTSLCTSBCTSSCTSKITGB3 | |
| SCHEMBL18224217 | 0.97 | CTSL (0.53) | CTSLCTSBCTSSCTSKITGB3 | |
| SCHEMBL16485550 | 0.97 | CTSL (0.53) | CTSLCTSBCTSSCTSKITGB3 | |
| SCHEMBL11239042 | 0.97 | CTSL (0.53) | CTSLCTSBCTSSCTSKITGB3 | |
| SCHEMBL13588070 | 0.95 | MME (0.56) | CTSLCTSBCTSSCTSKITGB3 | |
| SCHEMBL19065177 | 0.95 | MME (0.56) | CTSLCTSBCTSSCTSKITGB3 | |
| SCHEMBL27829774 | 0.95 | CTSL (0.57) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL8583909 | 0.94 | CTSL (0.53) | CTSLCTSBCTSSCTSKITGB3 | |
| SCHEMBL8583904 | 0.93 | CTSL (0.49) | CTSLCTSBCTSSCTSKITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120189524-A | Bispecific antibody-drug conjugate targeting B7H3 and EGFR and application thereof | 信达生物制药(苏州)有限公司 | 2025-06-24 | — | — | CN | claimed |
| WO-2025092983-A1 | B7-H3-TARGETING ANTIBODY-DRUG CONJUGATE AND USE THEREOF | 信达生物制药(苏州)有限公司 | 2025-05-08 | — | — | WO | claimed |
| CN-119925631-A | Antibody-drug conjugate targeting B7-H3 and application thereof | 信达生物制药(苏州)有限公司 | 2025-05-06 | — | — | CN | claimed |
| CN-119894535-A | Oritastatin derivatives and conjugates thereof | 祐方有限公司 | 2025-04-25 | — | — | CN | claimed |
| WO-2025067306-A1 | ANTIBODY-DRUG CONJUGATE TARGETING HER3 | 信达生物制药(苏州)有限公司 | 2025-04-03 | — | — | WO | claimed |
| WO-2025067446-A1 | ANTIBODY-DRUG CONJUGATE TARGETING TROP2, AND PREPARATION METHOD AND USE THEREFOR | 信达生物制药(苏州)有限公司 | 2025-04-03 | — | — | WO | claimed |
| CN-119630672-A | Camptothecin derivative and conjugate thereof, and preparation method and medical application thereof | 一线医药（杭州）有限公司 | 2025-03-14 | — | — | CN | claimed |
| US-20250049938-A1 | ANTIBODY-DRUG CONJUGATE AND USE THEREOF | SHANGHAI INSTITUTE OF BIOLOGICAL PRODUCTS CO., LTD. (CN) | 2025-02-13 | — | — | US | claimed |
| CN-119119176-A | Camptothecin derivatives | 伊缪诺金公司 | 2024-12-13 | — | — | CN | claimed |
| CN-113766954-B | Camptothecin derivatives | 伊缪诺金公司 | 2024-09-24 | — | — | CN | claimed |
| EP-4431521-A1 | ANTIBODY-DRUG CONJUGATE AND USE THEREOF | Shanghai Institute of Biological Products Co., Ltd. (CN) | 2024-09-18 | — | — | EP | claimed |
| CN-111051329-B | Hamiltelin derivatives and their antibody drug complexes | 住友制药株式会社 | 2024-07-30 | — | — | CN | claimed |
| WO-2023098691-A1 | ANTIBODY-DRUG CONJUGATE AND USE THEREOF | 上海生物制品研究所有限责任公司 | 2023-06-08 | — | — | WO | claimed |
| CN-116199740-A | Antibody drug conjugates and uses thereof | 上海生物制品研究所有限责任公司 | 2023-06-02 | — | — | CN | claimed |
| CN-115551552-A | Camptothecin derivatives and conjugates thereof | 祐方有限公司 | 2022-12-30 | — | — | CN | claimed |
| US-4415667-A | MIXING SWINE-PANCREATIC EXTRACT WITH DUODENUM TO ACTIVATE; PROTEOLYTIC ENZYMES; HYDROLASES | EISAI CO., LTD. (JP) | 1983-11-15 | — | — | US | claimed |
| JP-57150384-A | — | — | None | — | — | JP | disclosed |
| CN-120189524-A | Bispecific antibody-drug conjugate targeting B7H3 and EGFR and application thereof | 信达生物制药(苏州)有限公司 | 2025-06-24 | — | — | CN | disclosed |
| US-4242507-A | Sulfonic acid esters | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-12-30 | — | — | US | disclosed |
| EP-0010830-A2 | Dehydropeptides | Research Corporation (US) | 1980-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250049938-A1 | ANTIBODY-DRUG CONJUGATE AND USE THEREOF | QPCT, QPCTL, ARGLU1 | CTSL 1355/4885CTSB 3046/4885CTSS 3889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.